Highest-dose subgroup only: the mean one-year change in each measure, against a liver that turns over nearly 20% of its cells a year
The liver replaces nearly 20% of its cells every year.
So what happens to a CRISPR edit made inside it?
One year after a single infusion of an experimental CRISPR therapy called CTX310, the effect had not faded. ANGPTL3 and lipid levels stayed low and flat the whole time. The trial’s coinvestigator reports that the FDA has asked for these patients to be followed for 15 years.
What the one-year data showed
The data comes from a small Phase 1a trial in 15 adults. All of them had uncontrolled hypercholesterolemia, moderate to severe hypertriglyceridemia, or mixed dyslipidemia. The trial was open-label and ascending-dose.
Each person got one infusion of CTX310, between 0.1 and 0.8 mg/kg, set by estimated lean body weight. The trial was built to test safety first. The lipid numbers were a secondary endpoint.
The results were shown in a late-breaking session at the European Society of Cardiology Congress 2026. They were published the same day as a research letter in the New England Journal of Medicine. Cleveland Clinic describes it as the longest follow-up for a gene-editing approach to treating lipid disorders by targeting ANGPTL3.
The Phase 1a trial is now finished.
On safety, no dose-limiting toxicity was related to CTX310. No new serious adverse events were reported during the longer follow-up either.
ANGPTL3 and lipid levels stayed low and flat for the whole year.
Mean change at one year — highest dose (0.8 mg/kg) only
- ANGPTL3: −78.6% (range −89.0% to −63.2%)
- LDL cholesterol: −52.5% (range −84.2% to −24.4%)
- Triglycerides: −47.8% (range −77.6% to −14.7%)
- Apolipoprotein B: −37.2% (range −61.2% to −12.9%)
- These numbers come from the highest-dose group only. They are not the result across all 15 people in the trial, who got doses anywhere from 0.1 to 0.8 mg/kg.
What CTX310 actually does
CTX310 is CRISPR-Cas9 packed inside a lipid nanoparticle, the delivery vehicle that carries it to the liver. Inside are two parts: an mRNA and a guide RNA. Together they target one gene: ANGPTL3.
The aim is a permanent knockout in hepatocytes, the liver's main working cells. All of this happens in vivo. No cells are removed, edited, and returned.
ANGPTL3 is a protein the liver makes. The Cleveland Clinic report calls it "an important regulator of lipid metabolism by inhibiting lipoprotein and endothelial lipase."
Here is the part that matters: some people are born with a broken copy of this gene. They carry low LDL cholesterol and low triglycerides for life, and a lower risk of atherosclerotic cardiovascular disease. There is no evidence it does them any harm.
That is the whole reason for switching this gene off on purpose. Nature already ran the experiment.
Why cell turnover is the real question
A gene edit is only a one-time treatment if it stays put. And the liver is not a static tissue. Hepatocytes turn over at nearly 20% a year.
The average adult liver cell is under three years old, whatever the person's age.
So here is the risk. If the cells that were never edited keep dividing, they slowly outnumber the edited ones, and the effect fades. Nobody had watched long enough to know.
Cleveland Clinic reports no follow-up this long for a gene-editing approach to lipid disorders targeting ANGPTL3 before this readout.
Steven Nissen, MD, is a coinvestigator on the trial and Chief Academic Officer of Cleveland Clinic's Heart, Vascular & Thoracic Institute. He put the problem plainly.
"When you edit a gene, it raises the question of whether the effect is temporary or permanent because of cell turnover," he said. "We really need to know if this is a permanent alteration that can enable once-in-a-lifetime treatment."
His read of the one-year result is careful, not triumphant. "The good news is that the levels of ANGPTL3 and lipids remained low and flat through the full year, which suggests we're editing the genes so efficiently that when the hepatocytes replicate, the genetic change we've induced is replicated along with them."
Suggests is the word to hold on to. One year of flat levels shows the effect survived one year of that turnover. It isn’t proof that the edit is permanent, and the report doesn’t claim it is.
An investigator says the FDA asked for 15 years of follow-up
In the Cleveland Clinic report, Nissen says the FDA has asked for patients in this trial to be followed for 15 years. The report calls that an unprecedented length of required monitoring. The ask is not about whether the therapy works.
Nissen said it is "for reasons of safety rather than efficacy," and explained the concern: "We need to ensure there are no downstream safety issues from editing a gene, such as malignancy." He also said this programme will not be the only one carrying that load: "This type of very long-term follow-up will have to be done for most of the CRISPR-based therapies."
Fifteen years of follow-up — asked for on safety grounds, not because anyone doubts the effect.
One caveat matters before anyone quotes this as policy. It is a request reported by an investigator, about this one trial. It is not published FDA guidance and it is not a formal rule.
Do not repeat it as one.
What comes next
Phase 1a is done and Phase 1b will start soon. Luke Laffin, MD, is a Cleveland Clinic cardiologist who presented the data and is co-first author. He said that in Phase 1b every patient will get a "similar dose" of CTX310, and that the team "will look at the treatment's efficacy in specific lipid disorder cohorts, not the heterogeneous mix of participants that were studied in Phase 1a."
That narrower design is on purpose. It is where the durability signal gets its first real test in a group you can generalise from.
What this means for drug developers
Keep the read narrow, because the data is narrow. One programme. One target. One year. One small dose-ranging group. What travels beyond it is the method, not the number.
If flat levels at 12 months hold up in the bigger, cleaner groups of Phase 1b, durability changes status. It stops being something a developer claims and becomes something a developer measures. That changes what a Phase 1 package for an in vivo editing programme is expected to carry.
Laffin framed the wider read this way: "This is encouraging for the entire field of CRISPR, because it suggests that a one-and-done treatment approach really might be possible for many of the gene-editing targets now being looked at." Read that sentence slowly. Suggests and might are doing real work in it. Encouraging is not the same as established.
The 15-year ask is the part with a price tag attached today. Keeping a trial population traceable, consented and reachable for 15 years takes a registry and a budget line. It also takes a plan for limiting loss to follow-up.
You design that in at Phase 1. You do not bolt it on later.
Nissen's line that most CRISPR therapies will need this changes the picture. A one-trial condition becomes a planning assumption for anyone building in this space. Discovering it late is expensive in a way that planning for it early is not.
There is a lesson about picking targets sitting in plain sight here. ANGPTL3 was picked for a reason. Human genetics had already shown what a lifetime without it looks like: lower LDL cholesterol, lower triglycerides, lower cardiovascular risk, no sign of harm.
A target with that natural read-out makes a permanent edit far easier to argue — to a regulator, and to an investment committee.
If you've solved a problem like this, Regulatory Affairs experts get matched to paid consulting work through GTC's Expert Network — join free.
What this means for investors
The source report does not name the company behind the therapy. So what follows is about the data, not about a position.
The headline numbers belong to the highest-dose group. That one detail is where valuation mistakes get made.
A 78.6% mean drop in ANGPTL3 at 0.8 mg/kg is not the trial's result. All 15 people were dosed somewhere between 0.1 and 0.8 mg/kg.
The ranges are wide, too. Inside that same group, LDL cholesterol moved anywhere from −84.2% to −24.4%. Same dose, very different results.
A therapy sold as one-and-done still has to answer two questions. How many patients land at the shallow end of that range? And what happens to them next?
Phase 1b is built to narrow exactly that: one similar dose, specific lipid disorder cohorts, not a heterogeneous mix.
That is the readout that will test the durability claim in a group you can generalise from. This one opens the question. It does not close it.
The wider impact on the field
Cell turnover isn’t a lipid-programme problem. It is a question for any in vivo edit made in a tissue that rebuilds itself. That is why a flat 12-month curve in liver cells reads as more than one programme's update.
The report also notes two more papers on PCSK9 targeting since this trial's own 60-day results. Those earlier results appeared in the New England Journal of Medicine in late 2025. Data is arriving faster than the durability question can be closed for any single target.
The honest position today is a short one. One trial, one target, one organ, one year of stable levels.
That’s a lot more than the field had before. It’s a lot less than proof that gene editing is a one-time treatment.
What this means for a CGT program
ANGPTL3 and lipid levels stayed low and flat through the full year in the highest-dose group — one durability data point, from one platform, in one tissue, at one dose level.
GTC analysis: that is a platform decision as much as a science one. The editing platform is the therapeutic asset itself, developed in-house or in-licensed, not a CDMO or a reagent a program sources. Building on this signal means trusting data that is one year old, from a single tissue, at a single dose.
GTC analysis: ask what tissue, dose, and cohort any durability claim was actually measured under before extrapolating it to a different target or construct. One year in liver at one dose does not automatically transfer.
Frequently asked questions
What is CTX310, and what did the one-year data show?
CTX310 is CRISPR-Cas9 carried inside a lipid nanoparticle. It holds two parts: an mRNA and a guide RNA. Together they target one gene, ANGPTL3, aiming for a permanent knockout in liver cells. In the highest-dose (0.8 mg/kg) group of a Phase 1a trial, ANGPTL3 fell by a mean of −78.6% from the start to one year. At that same 0.8 mg/kg dose, LDL cholesterol fell −52.5%, triglycerides −47.8% and apolipoprotein B −37.2%. Those are highest-dose group figures. They are not the result across all 15 people in the trial, who got doses between 0.1 and 0.8 mg/kg.
Why does liver cell turnover matter for a CRISPR gene edit?
Liver cells turn over at nearly 20% a year. The average adult liver cell is under three years old, whatever the person's age. If the cells that were never edited keep dividing, they slowly outnumber the edited ones and the effect fades. That is not what happened. Coinvestigator Steven Nissen, MD, said the levels of ANGPTL3 and lipids stayed low and flat through the full year. He said that suggests the editing is efficient enough that the change is copied along with the liver cells when they divide.
Does one year of stable levels mean the edit is permanent?
No. The finding is one year of low, flat ANGPTL3 and lipid levels. The investigators describe that as a sign of efficient editing, not as proof the edit is permanent. Nissen stated the open question directly: "We really need to know if this is a permanent alteration that can enable once-in-a-lifetime treatment."
Why is 15 years of follow-up being reported for this trial?
In the Cleveland Clinic report, Nissen says the FDA has asked for patients in this trial to be followed for 15 years. The report calls that an unprecedented length of required monitoring. He said the ask is for safety reasons, not efficacy. The aim is to make sure that editing a gene causes no downstream safety problems, such as cancer. He also said very long follow-up will have to be done for most CRISPR-based therapies. This is a request reported by an investigator about this trial, not published FDA guidance.
What happens next with CTX310?
Phase 1a is finished and Phase 1b will start soon. Luke Laffin, MD, presented the data and is co-first author. He said every patient in Phase 1b will get a similar dose of CTX310. The team will look at how well the treatment works in specific lipid disorder groups, not the mixed group studied in Phase 1a.
AAV to AI, Edition 02
Get the weekly resource
Three signals across four published stories, with decision context to help CGT teams act earlier.
Free PDF, 40 pages.
Download Edition 02Sources
- Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year — Cleveland Clinic Consult QD, August 31, 2026. Every claim in this article traces to this report, including the one-year biomarker figures, the trial design, the FDA follow-up request, and all quoted remarks from Steven Nissen, MD and Luke Laffin, MD.
- Initial 60-day results, New England Journal of Medicine 2025;393:2119-2130 — cited within the Cleveland Clinic report above as the trial's earlier publication. Not independently retrieved for this article; no separate link is offered because none appears in the source.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.